Haeme-responsive gene (HRG)-1 encodes a 16-kDa transmembrane protein that is induced by insulin-like growth factor-1 (IGF-1) and associates with the vacuolar-(H þ ) ATPase (V-ATPase). We previously reported that HRG-1 is essential for V-ATPase activity in endosomal acidification and receptor trafficking. Here, we show that in highly invasive and migratory cancer cell lines, HRG-1 and the V-ATPase are co-expressed at the plasma membrane, whereas in less invasive cell lines and non-transformed cells HRG-1 overexpression remains confined to intracellular compartments. Stable suppression of HRG-1 in invasive breast cancer MDA-MB-231 cells decreases extracellular pH, cell growth, migration and invasion. Ectopic expression of HRG-1 in non-invasive MCF-7 cells enhances V-ATPase activity, lowers the extracellular pH and increases the pH-dependent activity of MMP2 and MMP9 matrix metalloproteinases. HRG-1 enhances trafficking of the glucose transporter-1 (GLUT-1) with a concomitant increase in glucose uptake and lactate production. HRG-1 also promotes trafficking of the insulin-like growth factor I receptor (IGF-1R), b1-integrin and IGF-1 signalling. Taken together, our findings indicate that HRG-1 expression at the plasma membrane enhances V-ATPase activity, drives glycolytic flux and facilitates cancer cell growth, migration and invasion. Thus, HRG-1 may represent a novel target for selectively disrupting V-ATPase activity and the metastatic potential of cancer cells.
INTRODUCTION
An acidic microenvironment, resulting from increased glycolysis, can increase tumour malignancy by promoting cell proliferation and invasion. However, a shift in glucose metabolism from oxidative phosphorylation towards aerobic glycolysis can alter intracellular pH resulting in cytosolic acidosis. 1 Tumour cells can prevent acidification of the cytosol by activating a number of pHregulating transporters; Na þ /H þ exchanger, 2 carbonic anhydrases (CA) such as CA IX and XII, 3 proton-linked monocarboxylate transporters 4 and enzymes such as the vacuolar-(H þ ) ATPase (V-ATPase; reviewed in Hernandez et al.
5
). V-ATPases are a family of ATP-dependent proton pumps found on the internal membranes of all eukaryotic cells and on the plasma membrane of certain cell types (reviewed in Toei et al. 6 ). V-ATPases consist of two multisubunit domains: The V 1 domain, which contains eight subunits (A-H) located on the cytoplasmic side of membranes, and functions in ATP hydrolysis; and the V 0 domain, comprising of six subunits (a, d, e, c, c 0 and c 00 ) which are embedded in membranes, and functions in the translocation of protons across the membrane. V-ATPases regulate intraendosomal and extracellular acidification. 7 Extracellular acidification is essential for normal physiological processes such as the acid/ base balance in specialized renal cells, 8 bone resorption by osteoclasts 9 and sperm maturation in the epididymis. 10 Certain tumour cells have been shown to target the V-ATPase to the plasma membrane, and this correlates with their metastatic potential. [11] [12] [13] [14] [15] The acidic extracellular environment provided by the V-ATPase not only facilitates an optimum pH for degradative enzymes, such as matrix metalloproteinases (MMPs) and cathespins, 1 but also provides a lower pH environment that facilitates the evolution of a drug-resistant, invasive and metastatic phenotype. 5 Several extrinsic regulatory factors control V-ATPase-mediated proton transport. 16 Glucose deprivation causes rapid and reversible V-ATPase disassembly, which was first characterized in yeast and insect cells. 17, 18 In renal epithelial cells, glucose regulates V-ATPase assembly and trafficking to different cellular membranes via the PI-3 kinase (PI-3K) signalling pathway. 19 Moreover, direct coupling occurs between components of the V-ATPase and glycolytic enzymes, providing further evidence for glucose in V-ATPase activity. 20, 21 However, the link between glucose sensing, cellular metabolism and V-ATPase activity remains unclear.
We previously demonstrated that haeme-responsive gene (HRG-1) regulates V-ATPase activity, which is essential for endosomal acidification. We also demonstrated that glucose-induced V-ATPase reassembly in endocytic compartments is reduced when HRG-1 is suppressed. 22 Here, we investigated whether HRG-1 is important for cancer cell invasiveness and glucose metabolism. Our results indicate that HRG-1 enhances V-ATPase activity and increases receptor trafficking, glucose uptake and glycolysis. Thus, HRG-1 has a key role in the interplay between cancer cell metabolism, pH of the microenvironment and metastatic propensity.
RESULTS HRG-1 and the V-ATPase proton pump are co-expressed at the plasma membrane of invasive cancer cells Plasma membrane-localized V-ATPases can enhance invasiveness. 11 HRG-1-enhanced V-ATPase function at the plasma membrane could facilitate a more aggressive cancer cell phenotype. Therefore, we examined HRG-1 and V-ATPase expression at the plasma membrane of several invasive and non-invasive cancer cells lines by flow cytometry, using an anti-HRG-1 monoclonal antibody and an antibody that specifically recognizes the V-ATPase a1 subunit (a1V 0 ). We found that in the highly invasive and migratory cell lines (MDA-MB-231, DU145 and ACHN), HRG-1 and the V-ATPase were coexpressed at the plasma membrane. However, in less invasive cancer cells and in non-transformed cells (MCF-7, LnCAP and NRK), HRG-1 is not expressed at the cell membrane, but is restricted to endocytic compartments (Figure 1a) . Cell surface colocalization of HRG-1 and V-ATPase was confirmed by immunofluorescence staining in MDA-MB-231 cells (Supplementary Figure S1A) .
We next asked whether modulation of HRG-1 expression could alter the distribution or assembly of the V-ATPase at the plasma membrane. Using two HRG-1-specific short hairpin RNA molecules that effectively suppress the expression of HRG-1 in MDA-MB-231 cells (sh-HRG-1 (a) and sh-HRG-1 (b)) by almost 80% compared with scramble controls (Figure 1b, Supplementary Figure S1B ), we observed decreased plasma membrane V-ATPase expression ( Figure 1b) . Conversely, overexpression of HRG-1 in MCF-7 (HA-HRG-1) cells resulted in increased plasma membrane expression of both HRG-1 and the V-ATPase compared with controls (HA-EV; Figure 1c ). Glucose deprivation causes disassembly of the V-ATPase, and we have shown previously that glucose-induced V-ATPase reassembly is reduced upon suppression of HRG-1. 22 Interestingly, HRG-1 can overcome the effect of glucose deprivation on V-ATPase assembly at the plasma membrane, and also further enhances membrane localization upon readdition of glucose in MCF-7 cells overexpressing HA-HRG-1 compared with control HA-EV (Supplementary Figure S1C) . The interaction of HRG-1 with V-ATPase subunits was confirmed by coimmunoprecipitation ( Supplementary Figures S2A-C) . Thus, HRG-1 is co-expressed with, and promotes the localization of the V-ATPase to the plasma membrane irrespective of glucose levels.
Suppression of HRG-1 in MDA-MB-231 cells decreases proton extrusion and promotes a less invasive phenotype V-ATPase inhibitors have previously been shown to reduce migration in cancer cells with high levels of plasma membrane localized V-ATPase. 23, 24 To investigate whether HRG-1 is required for the function of the V-ATPase at the plasma membrane, we assessed the effects of HRG-1 suppression on MDA-MB-231 cells by first measuring rates of proton extrusion and accumulation using the pH-sensitive probes pH Xtra and BCECF, respectively. Suppression of HRG-1 led to decreased rates of proton efflux ( Figure 2a ) and increased extracellular pH ( Figure 2b ).
As MMP activity is pH sensitive, and MMP2 is associated with V-ATPase-mediated invasion in certain cancer cell types, 25 we asked whether HRG-1 suppression affected MMP2 expression or activity. We observed that MMP2 protein expression was decreased in cells with suppressed HRG-1 compared with controls ( Figure 2c ). Zymography of cell supernatants also demonstrated decreased MMP2 activity in sh-HRG-1 MDA-MB-231 cells (Figure 2d ). Consistent with this, mRNA levels of both MMP2 and MMP9 were decreased in cells with suppressed HRG-1 expression (Figures 2e and f) .
We next assessed the migratory and invasive potential of MDA-MB-231 cells in which HRG-1 was stably suppressed with small hairpin RNA (shRNA). sh-HRG-1 MDA-MB-231 cell migration in transwell assays was reduced by approximately 40% compared with controls ( Figure 2g ). Invasion towards serum through matrigel-coated transwell was also reduced by 40% in MDA-MB-231 cells with suppressed HRG-1 (Figure 2h ). Chemotaxis assays based on invasion of cells into agarose spots into which insulinlike growth factor (IGF-1) is introduced also demonstrated inhibited cell invasion (by 40%), whereas MCF-7 cells that overexpressed HRG-1 exhibited increased invasion (by 15%) compared with controls (Supplementary Figure S3) . Taken together, these results indicate that HRG-1 suppression reduces migratory and invasive potential of cancer cells.
HRG-1 overexpression increases extracellular acidification, MMP expression and invasiveness of MCF-7 cells We next asked whether ectopic expression of HRG-1 at the plasma membrane promotes an invasive phenotype. To do this, we used MCF-7 cells stably transfected with HA-HRG-1 or empty vector, and measured extracellular acidification rates and pH. MCF-7 cells stably expressing HA-HRG-1 exhibited an increased rate of extracellular acidification resulting in a lower extracellular pH compared with controls (HA-EV; Figures 3a and b) . Inclusion of 2-deoxyglucose in the medium to suppress glycolysis (resulting in decreased lactate production: Supplementary Figure S4 ) partially reduced the increased rate of extracellular acidification in HA-HRG-1-overexpressing cells. The V-ATPase inhibitor bafilomycin A had a similar effect. Combining 2-deoxyglucose and bafilomycin A further reduced the rate of extracellular acidification and pH (Figures 3a and b) , suggesting that HRG-1-enhanced extracellular acidification is mediated by V-ATPase activity and glycolysis.
Zymography of the supernatants collected from cells overexpressing HA-HRG-1 and HA-EV controls indicated increased activity of both MMP9 and of pro-MMP2 (Figure 3c ). Similarly, increased MMP2 expression was observed in these cells (Figure 3d ). Levels of both MMP2 and MMP9 mRNA were also increased compared with controls (Figures 3e and f) . Taken together, these results indicate that HRG-1 facilitates a more invasive phenotype of cancer cells.
HRG-1 is required for cytosolic pH regulation by the V-ATPase An alkaline cytosolic pH facilitates cancer cell proliferation and growth, whereas acidification of the cytosol can result in apoptosis.
1 V-ATPases maintain a pH gradient not only between intracellular compartments and the cytosol but also between the cytosol and the extracellular milieu. HRG-1 promotes V-ATPasemediated extracellular acidification (Figures 2a and b) , but as the pH gradient between the intracellular and extracellular compartments is tightly regulated, we also investigated whether HRG-1 suppression alters cytosolic pH. We observed that MDA-MB-231 cells with stably suppressed HRG-1 exhibited increased acidification of the cytosol compared with control cells (Figure 4a ). HRG-1 suppression also reduced the colony-forming ability of MDA-MB-231 cells in soft agarose (Figure 4b ). Conversely, MCF-7 cells overexpressing HRG-1 exhibited a more alkaline cytosolic pH (Figure 4c) , and increased clonogenic growth in soft agarose that could be reversed with the V-ATPase inhibitor, bafilomycin A (Figure 4d ). Consistent with this, MCF-7 HA-HRG-1 cells were larger by at least 1 mM compared with controls ( Figure 4e ) and exhibited enhanced activation of the mammalian target of rapamycin signalling pathway (Figure 4f ).
Taken together, these data indicate that HRG-1-mediated regulation of the cytosolic/extracellular pH gradient facilitates cancer cell growth and survival.
HRG-1 promotes glucose uptake, lactate secretion and GLUT-1 trafficking to the plasma membrane We next turned our attention to the effects of HRG-1 on pH regulation in glucose metabolism. Previous studies demonstrated that glucose deprivation causes reversible disassembly of the V 0 / V 1 subunits in yeast and mammalian cells. 19 It has also been HRG-1 activates plasma membrane V-ATPase in cancer cells FM Fogarty et al proposed that intracellular pH can regulate V-ATPase assembly in response to changes in glycolytic flux. 26 Our data shows that HRG-1 suppression leads to cytosolic acidification and decreased V-ATPase assembly at the plasma membrane ( Figure 1b) and that HRG-1 enhances V-ATPase assembly in the presence of glucose (Supplementary Figure S1C) . As HRG-1 is not an integral component of the V-ATPase, we next investigated whether HRG-1 mediates a link between glucose metabolism, glycolysis and V-ATPase assembly.
We first investigated glucose uptake in MCF-7 HA-HRG-1 cells using the fluorescent glucose analogue 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG). This showed that the net uptake of glucose was increased by B60% in MCF-7 HA-HRG-1 cells compared with controls ( Figure 5a ). An approximate 40% decrease in glucose uptake was observed in MCF-7 cells in which HRG-1 was suppressed by small interfering RNA (Figure 5b ). The concentration of lactate in the culture medium correlated with increased glucose uptake in MCF-7 HA-HRG-1 cells, and was
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MDA-MB-231 increased by almost 50% compared with controls ( Figure 5c ). We also observed that lactate in the culture medium was markedly decreased in MDA-MB-231 cells with suppressed HRG-1 ( Figure 5d ). These data demonstrate that HRG-1 expression can alter glucose transport, glucose consumption and lactate secretion. Collectively, these data suggest that HRG-1 enhances glycolysis, which may also enhance the activity of the V-ATPase at the plasma membrane to maintain a more alkaline cytosol for cell growth. were analysed for extracellular proton concentration using the pH-sensitive dye BCECF. BCECF was excited at 490 and 440 nm and the emitted fluorescence measured at 535 nm. Data are presented as pH values determined from standard curves generated using pH-equilibrated cells. Graphs represent the mean fluorescence ± s.e.m. of three independent experiments (**Po0.005; Student's t-test). (c) Cell lysates from MDA-MB-231 stably expressing sh-SCR or HRG-1 shRNA (sh-HRG-1) were analysed by western blotting using the indicated antibodies. (d) Gelatinase activity was measured by zymography of the supernatants from MDA-MB-231cells stably expressing sh-SCR or HRG-1 shRNA (sh-HRG-1). Graph represents gelatinase activity normalized to control (sh-SCR)±s.e.m. of three independent experiments (*Po0.05; Student's t-test).
(e, f) RNA isolated from MDA-MB-231 cells stably expressing sh-SCR or HRG-1 shRNA (sh-HRG-1) was used for quantitative reverse transcriptase -PCR analyses of MMP2 and MMP9 expression. The data are expressed as fold activation normalized to cyclophillin ± s.e.m. of three independent experiments (**Po0.005; Student's t-test). (g, h) Migration and invasion of MDA-MB-231 cells stably expressing sh-SCR or HRG-1 shRNA (sh-HRG-1) were assessed using transwell assays. Cells were seeded into the upper chamber of the apparatus in serum-free medium and allowed to move towards serum in the lower chamber. Migration and invasion of sh-SCR cells were set at 100 and migration of sh-HRG-1 MDA-MB-231 is expressed relative to control. The data are represented as mean±s.e.m. of three independent experiments (**Po0.005; Student's t-test). Graph represents the mean cell size ± s.e.m. of three independent experiments (**Po0.005; Student's t-test). (f) Cell lysates from parental MCF-7 cells or MCF-7 cells stably expressing HA-EV or HA-HRG-1 cells were prepared and analysed by western blot using the indicated antibodies and fold change in PBp70S6K expression levels was quantified using the Odyssey software as described in Materials and methods and is indicated below the each band.
We have shown previously that HRG-1 enhances the trafficking of the transferrin receptor (TfnR); 22 as our results indicate that HRG-1 is involved in glucose metabolism, we investigated the trafficking of glucose transporter-1 (GLUT-1) in MCF-7 HA-HRG-1 cells. We found significant colocalization of GLUT-1 and HRG-1 at a perinuclear TfnR-positive compartment (Supplementary Figure  S5A) . We also observed more pronounced GLUT-1 expression at the plasma membrane compared with control cells, suggesting enhanced recycling (Figure 6a ). To determine whether the colocalization between GLUT-1 and HRG-1 was dependent on insulin-like signalling, we examined colocalization in cells that were starved of serum and glucose, and found that colocalization was not evident under these conditions (Figure 6b) . However, when cells were stimulated with glucose for 15 min, colocalization of HRG-1 and GLUT-1 was again observed in the perinuclear region (Figure 6c ). Pre-treatment of cells with the PI-3K inhibitor LY294002 prevented the effects of glucose in control cells (Figure 6d, top panel) . However, in MCF-7 HA-HRG-1 cells, inhibition of PI-3K did not prevent colocalization of HRG-1 and GLUT-1 (Figure 6d, bottom panel) . Moreover, although PI-3K inhibition restricted GLUT-1 re-localization from the plasma membrane to intracellular compartments, overexpression of HRG-1 partially prevented this, with GLUT-1 re-localizing to intracellular vesicles (Figure 6d, bottom panel) . Overexpression of HRG-1 did not affect GLUT-1 expression levels, suggesting that HRG-1 is exclusively involved in GLUT-1 trafficking (Figure 6e ). Taken together, these results indicate that HRG-1 only colocalizes with GLUT-1 under serum-/glucose-stimulated conditions, and this is not dependent on PI-3K activity. Furthermore, these data suggest that HRG-1 induced plasma membrane-localized GLUT-1 is not altered by PI-3K inhibition, and thus is not mediated by the ability of AKT to recruit GLUT-1 to the plasma membrane. 27, 28 We also investigated trafficking of other receptors that could contribute to cancer cell growth and migratory potential. IGF-1-induced phosphorylation of Akt and Erk were increased in MCF-7 HA-HRG-1 cells compared with controls ( Figure 7a ) and internalization rates of the IGF-1R were also increased (Figure 7b) . Moreover, when HRG-1 was suppressed with small interfering RNA in MCF-7 cells, we observed that total levels of IGF-1R and b1 integrin were reduced, this reduction was rescued by treatment with specific lysosomal protease inhibitors leupeptin and E64D (Figures 7c and d) , indicating that suppression of HRG-1 results in defective sorting of recycled receptors to the degradative compartment. HRG-1 levels were also sensitive to lysosomal protease inhibition (Figure 7d ). IGF-1-induced Akt phosphorylation was reduced and to a lesser extent Erk phosphorylation (20 min) in cells with suppressed HRG-1), compared with controls ( Figure 7e) .
Overall, these data suggest indicates an important function for HRG-1 trafficking of GLUT-1 and glucose uptake and for trafficking of key receptors that promote cancer cell metabolism, growth and migratory capacity.
DISCUSSION
Plasma membrane expression of V-ATPase proton pumps correlates with increased metastatic potential of cancer cells. [11] [12] [13] 29 Here, we demonstrate that HRG-1 enhances V-ATPase activity, glucose uptake and receptor recycling when expressed at the plasma membrane (summarized in Figure 7e ). Thus, HRG-1 has a unique role in V-ATPase activity with receptor trafficking and glycolysis to support an invasive cancer phenotype.
HRG-1 co-expression with V-ATPase at the plasma membrane is evident in highly migratory or invasive cancer cells. In non-invasive and non-transformed cells, this association is restricted to the endocytic pathway, although the V-ATPase is known to be active at the plasma membrane of certain kidney cells. 8 A recent study on location of haeme transporters and haeme oxygenases in epithelial cells demonstrated HRG-1 expression at the plasma membrane of non-polarized Hep-2 cells together with the haeme/folate transporter HCP-1 and the divalent metal transporter DMT1. In polarized epithelial MDCK cells, HRG-1 is located at the basolateral membranes, whereas HCP-1 and DMT1A-I are located in the apical membranes. 30 Enhanced expression of HRG-1 at the plasma membrane of migratory cancer cells is consistent with its role in receptor trafficking and haeme uptake, and with its induction by IGF-1 signalling. 22 Our results are also consistent with those of Sennoune et al. (2)) small interfering (siRNA) were incubated with dimethyl sulfoxide (vehicle) or lysosomal inhibitors leupeptin (Leu) and E64-d for 26 h and analysed for b1-integrin and IGF-1R expression by western blot (e) MCF-7 cells transfected with control (siNeg) or HRG-1-specific (siHRG-1(2)) siRNA were serum starved for 4 h, followed by stimulation with 10 ng/ml of IGF-1 for the indicated times. AKT and ERK activation was assessed by western blotting and normalized to control AKT and ERK expression. All data are typical of at least three independently performed experiments. (f ) Schematic representation of HRG-1 function at the plasma membrane of cancer cells. HRG-1 enhances V-ATPase activity at the plasma membrane, which facilitates a higher intracellular pH and a lower extracellular pH, promoting invasion and growth of cancer cells. Increased internalization and trafficking of cellular receptors including GLUT-1 is accompanied by increased glucose uptake and glycolysis, which also facilitates V-ATPase function. GLUT-1: glucose transporter-1; HRG-1: haeme-responsive gene-1; V-ATPase: vacuolar-H It is not surprising that as an IGF-1-responsive protein, HRG-1 function would facilitate cell growth in transformed cells. It is however intriguing that HRG-1 induction and association with the V-ATPase leads to regulation of cytosolic acidification, which is intimately linked with cell growth. 31 This is also likely to have important consequences for tumour cell survival in response to therapy. Altered cytosolic pH mediated by the V-ATPase has been implicated in drug resistance. 5, 14 For example, cisplatin-resistant cells have a more alkaline cytosolic pH compared with drugsensitive cells and have elevated expression of V-ATPase subunit genes. 32 Indeed, the V-ATPase is being actively pursued as a target in chemotherapy. 5 Classical proton pump inhibitors such as bafilomycin can reduce tumour growth in vivo, 33 and a range of new approaches to V-ATPase inhibition are also proposed. 5, 34 Our data suggest that HRG-1 expression reflects V-ATPase activity, and as it is sufficient to enhance V-ATPase activity, it may constitute a target for interrupting V-ATPase function in cancer cells.
It is well established that glucose regulates V-ATPase assembly in yeast and mammalian cells, and that disassembly of the V 1 and V 0 sectors occurs when glucose is limited or glycolysis is interrupted. Disassembly inactivates ATP hydrolysis and proton pumping, and this can be reversed by glucose re-addition. Glucose stimulation also promotes V-ATPase translocation to the plasma membrane. 19 We previously found that HRG-1 suppression reduces glucose-induced V-ATPase reassembly and we show here that HRG-1 enhances trafficking of the GLUT-1 to the plasma membrane. HRG-1-overexpressing cells increase glucose uptake and lactate secretion. It is therefore likely that the increased intracellular proton concentration associated with increased GLUT-1-mediated glucose uptake by HRG-1 enhances the activity of the V-ATPase at the plasma membrane. This could explain our observations of increased a1V 0 subunit expression at the plasma membrane of MCF-7 cells with overexpressed HRG-1 and decreased a1V 0 in MDA-MB-231 cells with suppressed HRG-1. This suggests that HRG-1 may have a role as the putative pH sensor for glucose in cells. This function has previously been ascribed to the V-ATPase accessory protein ATP6ap2 (prorenin receptor). 35 It is however conceivable that HRG-1 acts as a sensor through proton binding to its histidine-containing motifs.
HRG-1 enhances receptor trafficking in a pH-dependent manner. GLUT-1 trafficking to the membrane and increased glucose consumption supplies carbon to various anabolic pathways required for cancer cell growth and cell survival. 36 An increase in intracellular proton concentrations sensed by HRG-1 and/or the V-ATPase would in turn increase proton extrusion facilitating extracellular matrix-degrading enzymes and enhance invasive potential. Thus, by enhancing V-ATPase activity, HRG-1 may have a crucial role in linking receptor trafficking and glucose metabolism to pH regulation at the plasma membrane. Increased expression of HRG-1 provides a clear advantage to aggressive cancer cells. Thus, targeting HRG-1 and thereby its ability to regulate V-ATPase activity could be a novel therapeutic approach for limiting tumour survival, invasion and metastasis.
MATERIALS AND METHODS

Reagents and antibodies
Bafilomycin A, goat serum, crystal violet, Dulbecco's modified Eagle medium (DMEM), 2-NBDG, nigericin, TritonX-100, NaCl, leupeptin and E64-d were from Sigma Aldrich (Dublin, Ireland). The PI-3-K inhibitor (LY294002) was from Calbiochem (Darmstadt, Germany). BCECF and BCECF-AM were from Invitrogen (Paisley, UK). The following antibodies were used: anti-a1 V 0 rabbit polyclonal (H-140; Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-HA mouse monoclonal (HA.11; Covance, Leeds, UK); anti-GLUT-1 rabbit polyclonal (Abcam, Cambridge, UK); anti-MMP2 (Calbiochem); mouse anti-Akt, rabbit anti-phospho Akt (Ser473), rabbit anti-p 70 S6K, rabbit anti-phospho p 70 S6K (Cell Signalling Technologies, Danvers, MA, USA); anti-b actin (AC-15) antibody (Sigma Aldrich); anti-b1-integrin polyclonal (Millipore, Gillerica, MA, USA);. Cy2, Cy3 and Dylight488-conjugated Donkey anti-mouse and -rabbit antibodies were from Jackson Immunoresearch (Suffolk, UK). Goat anti-mouse and rabbit, 680 and 800 secondary antibodies were from LI-COR Biosciences (Cambridge, UK). The anti-HRG-1 monoclonal and polyclonal antibodies have been described previously. 
SDS-polyacrylamide gel electrophoresis and western blotting
Cellular protein extracts were prepared with a lysis buffer optimized for extraction of HRG-1 (0.2% Triton X-100, 250 mM sucrose, 20 mM Tris, pH 7.4, 1 mM dithiothreitol, supplemented with the tyrosine phosphatase inhibitor 1 mM Na 3 VO 4 and protease inhibitors, 1 mM phenylmethylsulfonyl fluoride, 1 mM Pepstatin, 1.5 ug/ml Aprotonin) for 30 min on ice. To analyse lysosomal degradation in HeLa and MCF-7 cells transfected with small interfering RNA-targeting HRG-1, culture media was changed 24 h after transfection to media supplemented with 1 mg/ml Leupeptin and 5 mg/ml E64-d. Media containing inhibitors were changed every 12 h and cells were treated for a total of 26 h. Typically, 30-50 mg of protein was resolved by 4-20% SDSpolyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose membrane and blocked for 1 h at room temperature in 5% milk in Tris-buffered saline-T (20 mM Tris, 150 mM NaCl and 0.05% Tween 20, pH 7.6). Primary antibodies were diluted in 5% milk in Tris-buffered saline-T and incubated with membranes at 4 1C for 18 h. IRdye-conjugated secondary antibodies were used for detection with the Odyssey Image Scanner System (LI-COR Biosciences) and the Odyssey quantification software.
Immunofluorescence and flow cytometry Cells were seeded on serum-coated 10-mm glass coverslips, washed with phosphate-buffered saline, fixed with 3.0% paraformaldehyde in phosphate-buffered saline and permeabilized using Permeabilize, Reduce, Denature (PRD) buffer (10% SDS, b-mercaptoethanol, 10% FBS/phosphatebuffered saline) for 30 min at 37 1C. Cells were incubated for 1 h with the indicated primary antibodies diluted in PFT buffer (Phosphate buffered saline (PBS) containing 4% FBS and .1% Triton X-100), washed with PFT buffer followed by incubation with Cy2-or Cy3-conjugated secondary antibodies together with Hoechst, images were acquired using a SPOT charge-coupled device camera mounted on a Nikon T600 fluorescent microscope (Kingston Upon Thames, UK). at Â 100 magnification. Analysis of plasma membrane expression of HRG-1 by flow cytometry was carried out as described previously. 22 Glucose uptake assays Cells were cultured at 50% confluence in six-well plates, which were placed on ice and the cells washed once with ice-cold incubation buffer (140 mM NaCl, 5.4 mM KCL, 0.5 mM MgCl 2 , 0.4 mM MgSO 4 , 3.3 mM NaHCO 3 , 2mM CaCl 2, 10 mM hydroxyethyl piperazineethanesulfonic acid, 5.5 mM glucose, pH 7.4). 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) (Molecular Probes, Hamburg, Germany) (100 mM) diluted in incubation buffer was added to each sample well and incubated at 37 1C for 15 min. Uptake was halted by washing with ice-cold trypsin for 10 min before resuspension in ice-cold complete DMEM. Samples were transferred to fluorescence-activated cell sorting tubes on ice, washed three times with ice-cold Hank's Balanced Salt Solution and the fluorescence intensity of 2-NBDG measured by flow cytometry (FACScalibur) in the FL1 fluorescence channel using CellQuest software (Becton Dickenson, Oxford, UK).
Lactate measurement
Cells (1 Â 10 6 cells per well) seeded in a six-well plate were cultured for 12 h at which time the media was replaced with 1 ml of fresh media. The lactate concentration in the cells was measured after 4 h according the manufacturer's instructions using an L-Lactic acid kit (Megazyme International, Wicklow, Ireland).
RNA isolation and quantitative RT-PCR
Total RNA was isolated using the Trizol method and cDNA synthesis was carried out by reverse transcription with equal amounts of RNA (2 mg) using a cDNA synthesis kit (Invitrogen). Quantitative PCR was carried out using the LightCycler instrument; Roche Molecular Biochemicals (East Sussex, UK) with QuantiTect SYBR Green technology (Qiagen, Crawley, West Sussex, UK) using primers described in Supplementary Table 1 . The delta-delta CT method was used to analyse data and determine relative mRNA expression levels.
Measurements of intracellular and extracellular pH
Extracellular pH was measured using the pH-sensitive dye BCECF (Invitrogen) using the protocol described by Lu., et al. 37 Briefly, following 12 h incubation in DMEM medium (25 mmol/l NaHCO 3 (pH 7.0)), the cells were washed twice using 0.9% NaCl, before being replaced with 120 ml serum-free HCO 3 À -buffered DMEM medium (1 mmol/l NaHCO 3 (pH 7.0)) for 12 h. Cell supernatant (100 ml) was added to 10 mM BCECF. The sample was excited at 490 and 440 nm and the emitted fluorescence detected at 535 nm using a micro plate spectrofluorimeter (Molecular Probes). Extracellular pH was determined using a curve plotted by the fluorescence 490/440 ratio of standard DMEM medium containing 10 mmol/l BCECF with a series of pH (5.5-7.5) buffered by HCO 3. Cytosolic pH was measured using BCECF-AM (Invitrogen) using a protocol described by Nilsson et al. 38 Cytsolic pH was determined using a curve generated by the fluorescence 490/440 ratio of standard potassium phosphate buffers containing 10 mmol/l BCECF-AM. Potassium phosphate buffers were prepared by titrating 135 mM K 2 HPO 4 and 20 mM NaCl against a solution containing 110 mM KH 2 PO 4 and 20 mM NaCl to pH 5.5, 6.0, 6.5, 7.0 and 7.5. Assays for rates of extracellular acidification were performed as previously described 39 using a hydrophilic long-decay fluorescent pHsensitive lanthanide probe (Luxel Biosciences, Cork, Ireland) and measured kinetically on a multilabel plate reader Victor 2 instrument.
Gelatin zymography and MMP expression MMP2 expression in cells and extracellular medium was assayed by western blotting. MMP activity in the media was assessed by gelatin zymography in SDS-polyacrylamide gel electrophoresis (10% containing 1 mg/ml gelatin) as described by Lu et al.
37
In vitro cell invasion, migration and plating efficiency assays
To measure cell migration and invasion, cell suspensions, at a final concentration of 2.5 Â 10 4 cells per 500 ml in DMEM, were loaded in triplicate into the upper wells of a transwell chamber (8.0 mm pore size;
